Abingworth’s Spyre Therapeutics SYRE Stock Holding History

Abingworth’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$108K	Hold	9,620	–	–	0.04%	17
2022 Q3	$127K	Hold	9,620	–	–	0.04%	18
2022 Q2	$121K	Hold	9,620	–	–	0.04%	20
2022 Q1	$553K	Hold	9,620	–	–	0.16%	17
2021 Q4	$1.14M	Hold	9,620	–	–	0.28%	16
2021 Q3	$1.91M	Hold	9,620	–	–	0.43%	16
2021 Q2	$1.67M	Hold	9,620	–	–	0.52%	14
2021 Q1	$1.9M	Hold	9,620	–	–	0.65%	14
2020 Q4	$1.89M	Hold	9,620	–	–	0.65%	11
2020 Q3	$1.7M	Hold	9,620	–	–	0.36%	13
2020 Q2	$2.22M	Hold	9,620	–	–	0.62%	13
2020 Q1	$1.1M	Hold	9,620	–	–	0.73%	13
2019 Q4	$1.83M	Hold	9,620	–	–	0.89%	10
2019 Q3	$1.85M	Hold	9,620	–	–	1.17%	8
2019 Q2	$1.64M	Hold	9,620	–	–	0.63%	9
2019 Q1	$1.93M	Buy	+9,620	New	+$2.01M	1.73%	9

Other funds holding SYRE

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Abingworth's SYRE Position: Q4 2022 in Review

Abingworth held its Spyre Therapeutics (SYRE) position steady in Q4 2022 at 9,620 shares worth $108K. The position accounts for 0.04% of the portfolio, ranked #17.

Abingworth first reported a position in SYRE in Q1 2019 and has held it in 16 quarters since. The position peaked at $2.22M in Q2 2020. 50 funds tracked by Wall St. Rank hold SYRE as of Q4 2022.

Abingworth held 9,620 shares of Spyre Therapeutics worth $108K as of Q4 2022.
Abingworth left its Spyre Therapeutics share count unchanged in Q4 2022.
Spyre Therapeutics made up 0.04% of Abingworth's portfolio in Q4 2022, its #17 holding.
Abingworth first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 16 quarters since.
Abingworth's Spyre Therapeutics position peaked at $2.22M in Q2 2020.
50 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.